Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal dexmedetomidine plus esketamine for sedation and postoperative delirium in pediatric burn scar laser treatment
ChiCTR2500106780Phase 4Not yet recruiting
- Sponsor
- Wuhan Third Hospital
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of dexmedetomidine, esketamine and propofol in Procedural anxiety, separation anxiety disorder (SAD), postoperative delirium (POD) and 1 more (2 arms), sponsored by Wuhan Third Hospital. Primary endpoints: Ramsay sedation score, Parental Anxiety Scores at separation (PSAS) and 2 more. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
dexmedetomidineesketaminepropofol
03
Conditions
Procedural anxietyseparation anxiety disorder (SAD)postoperative delirium (POD)Pain associated with burn scar procedures
Beyond the preview
Go deeper on ChiCTR2500106780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500106780.